Drugs / Donor-derived Mesenchymal Stromal Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03504241 | Jul 2018 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived Mesenchymal Stromal Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03504241 ↗ |
| Modality | Cell therapy | “These MSCs are a cellular product derived from bone marrow” NCT03504241 ↗ |